<DOC>
	<DOCNO>NCT01889667</DOCNO>
	<brief_summary>The purpose study test safety pharmacodynamics oral formulation insulin subject Type 2 Diabetes .</brief_summary>
	<brief_title>Safety , Pharmacokinetics ( PK ) Pharmacodynamics ( PD ) Multiple Oral Bedtime Doses ORMD-0801 Adult Patients With Type 2 Diabetes Mellitus ( T2DM )</brief_title>
	<detailed_description>This single-center , Phase II ( ) , randomize , double-blind , placebo-controlled , parallel group , inpatient study precede 5-day single-blind outpatient placebo run-in period .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Male female patient , age 20 70 year , inclusive T2DM ; At randomization , patient treat diabetes diet exercise , diet , exercise metformin ( &gt; 1000 mg/day ; type regimen ) . Patients stable regimen metformin ( define metformin dose type ) least 6 week prior enter placebo runin period . Other antidiabetic agent use 6 week prior enter placebo runin period ; 25 kg/m2 ≤ BMI ≤ 40 kg/m2 6.5 % ≤ HbA1c ≤ 10.5 % , prior randomization ) Fasting plasma glucose ≥ 126 mg/dL ( 8.3 mmo1/L ) prior randomization ; No tobacco nicotine use within 10 wks prior screen ; Females childbearing potential must negative serum pregnancy test result screen negative urine pregnancy test Visit 3 . Females nonchildbearing potential define postmenopausal : 1. 24 month since last menstrual cycle menopausal level FSH ; 2. age &gt; 55 year old ; 3. surgically menopausal . Presence clinically significant endocrine disease accord PI ; Clinical diagnosis T1DM ; Fasting plasma glucose &gt; 260 mg/dL end washout/stabilization/runin period ; Evidence unawareness hypoglycemia , document plasma glucose ≤ 50 mg/dL absence symptom hypoglycemia ; Presence clinically significant condition might interfere evaluation study medication ; Presence history cancer within past 5 yr . exception adequatelytreated localized basal cell skin cancer situ uterine cervical cancer ; Laboratory abnormality screen : 1 . Cpeptide &lt; 1.0 ng/mL ; 2 . Positive pregnancy test female childbearing potential ( screen start runin period ) ; 3 . Abnormal TSH level &gt; 1.5 x upper limit normal ; 4 . Positive test hepatitis B surface antigen and/or hepatitis C antibody ; 5 . Positive test HIV ; 6 . Any relevant abnormality interfere efficacy safety assessment study drug administration ; Use follow medication 1 . History use insulin 1 wk last 6 mo none last 6 wks prior randomization ; 2 . History use aprotinin time prior screen visit ; 3 . Administration antidiabetic drug metformin within 6 wks prior runin period ; 4 . Administration thiazolidinedione treatment within 3 month prior randomization ; 5 . Administration thyroid preparation thyroxine ( except patient stable replacement therapy ) within 6 week prior screen visit ; 6 . Administration systemic longacting corticosteroid within two month prolong use systemic corticosteroid inhale corticosteroid within 30 day prior screen visit ; 7 . Use medication know modify glucose metabolism decrease ability recover hypoglycemia oral , parenteral , inhaled steroid , beta blocker ( exception beta blocker ophthalmic solution glaucoma ocular hypertension ) , immunosuppressive immunomodulating agent . History severe multiple allergy ; History tobacco nicotine use within 10 wks prior screen Patient weight loss program maintenance phase , patient start weight loss medication within 8 wks prior screen ; Pregnancy breastfeeding ; Patient screen visit systolic blood pressure ≥165 mm Hg diastolic blood pressure ≥100 mm Hg . Patients allow take BP rescue medication long affect glucose metabolism ( e.g. , diuretic ) sensation hypoglycemia ( e.g. , betablockers ) ; Patient , time signing informed consent , user recreational illicit drug recent history ( within last year ) drug alcohol abuse dependence ; Elevated liver enzyme ALT , AST , alkaline phosphatase ) &gt; 2 x upper limit normal screening ; Very high triglyceride level ( &gt; 600 mg/dL ) screening ; ECG abnormality screen CV . Clinically significant CV include 1. history stroke , transient ischemic attack , MCI within 6 month prior screen ; 2. history currently NYHA Class IIIV heart failure prior screening ; 3. uncontrolled hypertension define BP ≥180 mmHg ( systolic ) ≥110 mmHG ( diastolic ) screen Visit 2 ; One contraindication metformin ; History gastrointestinal disorder potential interfere drug absorption ; At Principal Investigator 's discretion , condition factor deem unsuitable patient enrollment study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Oral Insulin</keyword>
	<keyword>Diabetes Mellitus Type 2</keyword>
	<keyword>Safety</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>